To Get more Insights,  Request A Free Sample 

 Which Products Are Currently Dominating Laboratory Procurement?

Two specific categories are outperforming others in the cell culture consumables and equipment market: Single-Use Systems (SUS) and specialized culture media. The single-use bioprocessing segment alone reached a valuation of USD 34.91 billion in 2024. Adoption rates are staggering, with 87% of biomanufacturing facilities now integrating disposable technologies. Stakeholders prefer these products—such as bioreactor bags, tubing assemblies, and filtration units—because they eliminate cleaning validation costs and reduce cross-contamination risks.

On the consumables side, the shift toward defined, animal-free inputs is reshaping procurement. The serum-free media market is now valued at roughly USD 1.90 billion, with 73.7% of this revenue generated specifically by biopharmaceutical production applications. CHO (Chinese Hamster Ovary) cell culture media remains the gold standard, commanding a 31% market share. Labs are aggressively replacing fetal bovine serum (FBS) with chemically defined alternatives to ensure regulatory compliance and batch-to-batch consistency.

Where Are the High-Growth Revenue Opportunities Hiding?

The most lucrative opportunities in the cell culture consumables and equipment market lie within the rapid adoption of specialized, single-use technologies. With the single-use bioprocessing sector reaching a valuation of USD 34.91 billion in 2024, the path forward is clear. Investors and manufacturers should focus on disposable components, which are forecasted to grow at a CAGR of 14.9%. This shift is driven by the industry’s need for speed; 87% of facilities have already integrated these systems to reduce downtime.

Moreover, the commercialization of Cell and Gene Therapy (CGT) has cracked open a high-value niche for premium consumables. Following the FDA approval of 9 new therapies in 2024, there is an immediate, critical need for clinical-grade viral vectors and specialized media. The serum-free media market alone represents a USD 1.90 billion opportunity, fueled by developers who raised USD 10.9 billion in the first half of 2024 to bring these drugs to market. Additionally, the integration of Artificial Intelligence is creating a parallel revenue stream. With the lab automation market valued at USD 5.76 billion, suppliers who develop "robot-ready" consumables—plastics compatible with automated arms and sensors—stand to capture significant market share from legacy providers.

Who Are the Key Titans Orchestrating Market Supply?

The competitive landscape of the cell culture consumables and equipment market is dominated by a few heavyweights who are aggressively consolidating their positions through massive capital expenditure. Thermo Fisher Scientific remains a central figure, having committed USD 2 billion to expand its US manufacturing and engineering footprint through 2025. Their influence is bolstered by a massive USD 1.4 billion R&D spend in 2024, ensuring they stay ahead in product innovation.

Cytiva is another dominant force in the cell culture consumables and equipment market, currently executing a USD 1.6 billion global capacity expansion plan. Their strategy focuses heavily on securing the supply chain for resins and single-use technologies. Merck KGaA is also highly active, having completed a EUR 180 million expansion of their Schnelldorf distribution center to streamline European logistics. Meanwhile, Fujifilm Diosynth Biotechnologies is challenging the status quo with a USD 1.2 billion investment in North Carolina, creating 680 jobs and signaling their intent to capture a larger slice of the CDMO market.

How Are Clinical Breakthroughs and Innovation Redefining Product Needs?

Innovation in clinical research is fundamentally altering what researchers buy in the cell culture consumables and equipment market. The explosion of AI in drug discovery is creating a need for high-throughput, automated equipment. In Q3 2024 alone, the industry saw USD 1.7 billion in AI-related pharmaceutical deals—a 310% spike in value. These AI-driven workflows require distinct, standardized consumables that can be handled by robotic arms without human intervention.

Furthermore, the rise of advanced therapies is driving demand for specialized 3D cell culture equipment. With 2,500 active IND applications on file with the FDA, researchers are moving away from 2D flat petri dishes to 3D spheroids and organoids that better mimic human biology. This shift supports the USD 5.76 billion lab automation market. Equipment that allows for real-time monitoring of cell health in 3D environments is seeing premium pricing and rapid adoption.

What Prominent Trends Are Determining Future Market Momentum?

Sustainability has emerged as the most prominent trend shaping the momentum of the cell culture consumables and equipment market. The industry is under immense pressure to address its environmental footprint, generating an estimated 300 million tons of plastic waste annually. With supply-chain emissions accounting for 80% of the industry's carbon output, procurement departments are now mandating "green" credentials.

Suppliers are responding with tangible innovations. For example, Avient launched bio-tubing in 2024 that reduces the product carbon footprint by 25%. Recycling programs are also becoming a standard service offering; a single MilliporeSigma facility successfully recycled 1,671 lbs of plastic recently. Consequently, the market is witnessing a "circular economy" push where the recyclability of single-use plastics is just as important as their performance. Stakeholders who fail to adapt to these sustainability metrics risk losing contracts with major pharma partners who have set aggressive Net Zero targets.

Segmental Analysis

High-Volume Testing and Infrastructure Stability Anchor Hospital and Lab Dominance

Hospitals and Diagnostics Laboratories remain the primary revenue generators in the cell culture consumables and equipment market, solidified by their role as the central gatekeepers of clinical decision-making. The Centers for Disease Control and Prevention (CDC) validates that 70% of medical decisions depend on laboratory data, making these facilities critical infrastructure. In 2024, this dominance was quantified by robust financial performances from the sector's largest players: LabCorp reported a 7.0% revenue increase to $13.0 billion, while Quest Diagnostics saw revenues rise 6.7% to $9.87 billion, driven by a "strong commercial focus on physicians and hospitals" and a 5% organic growth in base testing volumes.

This segment's leadership is further entrenched by regulatory stability. The 2025 Clinical Laboratory Fee Schedule (CLFS) update, following congressional action in late 2024, delayed significant payment cuts for clinical tests, preserving the financial viability of hospital and independent labs through 2025. Unlike decentralized Point-of-Care settings, centralized laboratories possess the capital and accreditation to handle high-complexity, high-reimbursement testing—such as oncology genomics and mass spectrometry. This capacity allows them to capture the vast majority of industry value, as evidenced by Siemens Healthineers reporting 5.6% comparable revenue growth in late 2024, largely sustained by hospital imaging and diagnostic workflows.

By Product, Recurring Revenue and Molecular Reagent Demand Drive Consumables Leadership

The Consumables segment—comprising reagents, assay kits, and media—maintains undisputed dominance in the cell culture consumables and equipment market, fueled by the industry’s reliance on the "razor-and-blade" business model where installed instruments mandate continuous, high-margin reagent purchasing. Thermo Fisher Scientific’s 2024 Annual Report confirms this disparity, reporting that Consumables generated US$ 17.59 billion in revenue. Similarly, Danaher Corporation’s 2024 financial overview highlights that approximately 65% of its total revenue is now recurring, driven primarily by consumable sales in diagnostics and life sciences. 

This segment’s rapid expansion is propelled by the structural shift toward molecular diagnostics and automated immunochemistry in the cell culture consumables and equipment market. Roche Diagnostics reported in January 2025 that its base business (excluding COVID-19) grew 8% in 2024, explicitly attributing this surge to "higher demand for immunodiagnostic, pathology, and molecular solutions." Furthermore, the rise of closed-system automation—such as Abbott's GLP Systems Track—locks laboratories into proprietary reagent ecosystems, ensuring long-term revenue visibility. With the global burden of chronic diseases requiring daily testing (e.g., glucose strips, cardiac biomarkers), consumables serve as the indispensable financial engine of the IVD market, offering resilience against economic volatility that capital-heavy instrument sales cannot match.

 To Understand More About this Research:  Request A Free Sample 

Regional Analysis 

Where is the Global Demand Density Most Concentrated in the Market?

North America remains the undisputed revenue powerhouse for the cell culture consumables and equipment market. The region's dominance is anchored by an unparalleled density of research infrastructure. In 2024, developers delivered a record 21.3 million sq. ft. of life sciences lab space across major US hubs. The Boston-Cambridge cluster alone had 15.9 million sq. ft. under construction, creating an immense vacuum for new equipment.

However, the nature of this demand is evolving. With biopharma venture capital raising USD 26 billion in 2024, US-based biotech startups are well-funded, driving high-volume orders for initial lab setups. Yet, while innovation stays in the West, the geography of volume manufacturing is shifting.

How Asia Pacific Becoming the New Engine of Manufacturing Growth?

Asia Pacific is rapidly transforming from a cost-saving destination into a strategic innovation hub. The region is playing a critical role in shaping cell culture consumables and equipment market growth, driven by government incentives and localizing supply chains. India and South Korea are at the forefront of this trend. Sartorius, for instance, invested EUR 270 million to expand its activities in South Korea, recognizing the country's growing bio-processing capabilities.

Similarly, Corning invested USD 60 million (INR 500 Crore) to build a borosilicate glass vial facility in Hyderabad, India. This move addresses the local need for high-quality packaging for vaccines and biologics. With the Serum Institute of India targeting an annual capacity of 4 billion doses, the region's appetite for culture media and vials is voracious. The Asia Pacific market is expanding faster than its Western counterparts, fueled by a dual demand for domestic vaccines and export-grade biosimilars.

Key Recent Developments Shaping the Cell Culture Consumables and Equipment Market 

1. Cytiva – larger single-use bioreactors (Mar 2025)
   Cytiva expanded its Xcellerex X-platform with new 500 L and 2000 L single-use bioreactors to help scale advanced therapeutics from 50 L to 2000 L while improving efficiency and reducing risk in upstream cell culture operations.​
2. Culture Biosciences – cloud-integrated mobile bioreactor (Apr 2025)
   Culture Biosciences launched Stratyx 250, described as the first cloud-integrated, mobile bioreactor for cell culture process development, enabling remote monitoring, automation, and AI-driven optimization of bioprocess parameters.​
3. PHC & Cyfuse – 3D cell product production tech (Mar 2025)
   PHC Holdings and Cyfuse introduced a production technology that allows real-time quality monitoring of 3D cell products, targeting more efficient and controlled manufacturing of complex cell-based constructs.​
4. Merck (MilliporeSigma) – GMP media line in China (2024, live into 2025)
   Merck announced the start of commercial production on its first GMP-compliant manufacturing line for cell culture media in China, expanding regional supply capacity for media and related consumables.​
5. Univercells Technologies (Donaldson) – scale-X nexo mini fixed-bed bioreactor (Oct 2024)
   Univercells Technologies launched the scale-X nexo, a miniaturized fixed‑bed bioreactor with a 0.5 m² growth surface designed for cost-effective, scalable cell culture in early process development for cell and gene therapy and vaccines.​

Top Companies in the Cell Culture Consumables and Equipment Market

• Agilent Technologies, Inc
• Corning Incorporated
• Danaher Corporation
• Eppendorf AG
• FUJIFILM Irvine Scientific, Inc
• Getinge AB
• Lonza Group AG
• Merck KGaA
• Sartorius AG
• Thermo Fisher Scientific Inc
• Other Prominent Players

Market Segmentation Overview

By Product

• Equipment
• Consumables

By End User

• Hospitals & Diagnostics laboratories
• Pharmaceuticals & Biotechnology Companies
• Research & Academic Institutes
• Others

By Region

• North America
  • The US
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia and New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America